256 related articles for article (PubMed ID: 31486991)
1. Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome.
Bicer M; Alarslan P; Guler A; Demir I; Aslanipour B; Calan M
J Endocrinol Invest; 2020 Mar; 43(3):305-313. PubMed ID: 31486991
[TBL] [Abstract][Full Text] [Related]
2. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome.
Demi R İ; Guler A; Alarslan P; Isil AM; Ucman O; Aslanipour B; Calan M
Endocrine; 2019 Jul; 65(1):175-183. PubMed ID: 31154608
[TBL] [Abstract][Full Text] [Related]
3. Decreased levels of spexin are associated with hormonal and metabolic disturbance in subjects with polycystic ovary syndrome.
Guler A; Demir İ
J Obstet Gynaecol; 2021 Apr; 41(3):408-413. PubMed ID: 32293212
[TBL] [Abstract][Full Text] [Related]
4. Free androgen index and Irisin in polycystic ovary syndrome.
Li H; Xu X; Wang X; Liao X; Li L; Yang G; Gao L
J Endocrinol Invest; 2016 May; 39(5):549-56. PubMed ID: 26584566
[TBL] [Abstract][Full Text] [Related]
5. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
6. Association of decreased myonectin levels with metabolic and hormonal disturbance in polycystic ovary syndrome.
Demir İ; Guler A
Gynecol Endocrinol; 2020 Nov; 36(11):947-950. PubMed ID: 32314610
[TBL] [Abstract][Full Text] [Related]
7. Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome.
Bicer M; Alan M; Alarslan P; Guler A; Kocabas GU; Imamoglu C; Aksit M; Bozkaya G; Isil AM; Baloglu A; Aslanipoiur B; Calan M
J Endocrinol Invest; 2019 Mar; 42(3):303-312. PubMed ID: 29956214
[TBL] [Abstract][Full Text] [Related]
8. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
9. Association between circulating zinc-α2-glycoprotein levels and the different phenotypes of polycystic ovary syndrome.
Tang C; Li X; Tang S; Wang Y; Tan X
Endocr J; 2020 Mar; 67(3):249-255. PubMed ID: 31748429
[TBL] [Abstract][Full Text] [Related]
10. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome.
Norman RJ; Hague WM; Masters SC; Wang XJ
Hum Reprod; 1995 Sep; 10(9):2258-61. PubMed ID: 8530647
[TBL] [Abstract][Full Text] [Related]
11. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome.
Zhang L; Fang X; Li L; Liu R; Zhang C; Liu H; Tan M; Yang G
J Endocrinol Invest; 2018 Dec; 41(12):1401-1407. PubMed ID: 29785700
[TBL] [Abstract][Full Text] [Related]
12. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index.
Bizzarri C; Benevento D; Ravà L; Patera IP; Schiaffini R; Ciampalini P; Giannone G; Cappa M
Fertil Steril; 2011 Dec; 96(6):1497-1502.e1. PubMed ID: 21982726
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
[TBL] [Abstract][Full Text] [Related]
14. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome.
Alan M; Gurlek B; Yilmaz A; Aksit M; Aslanipour B; Gulhan I; Mehmet C; Taner CE
Gynecol Endocrinol; 2019 Mar; 35(3):220-223. PubMed ID: 30325247
[TBL] [Abstract][Full Text] [Related]
15. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.
Sova H; Unkila-Kallio L; Tiitinen A; Hippeläinen M; Perheentupa A; Tinkanen H; Puukka K; Bloigu R; Piltonen T; Tapanainen JS; Morin-Papunen L
Gynecol Endocrinol; 2019 Jul; 35(7):595-600. PubMed ID: 30668196
[TBL] [Abstract][Full Text] [Related]
16. Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome.
Belan M; Pelletier C; Baillargeon JP
Metab Syndr Relat Disord; 2017 Apr; 15(3):145-152. PubMed ID: 28339345
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance, androgens, and lipids are gradually improved in an age-dependent manner in lean women with polycystic ovary syndrome: insights from a large Caucasian cohort.
Livadas S; Macut D; Bothou C; Kuliczkowska-Płaksej J; Vryonidou A; Bjekic-Macut J; Mouslech Z; Milewicz A; Panidis D
Hormones (Athens); 2020 Dec; 19(4):531-539. PubMed ID: 32451980
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?
Catteau-Jonard S; Bancquart J; Poncelet E; Lefebvre-Maunoury C; Robin G; Dewailly D
Ultrasound Obstet Gynecol; 2012 Aug; 40(2):223-9. PubMed ID: 22648908
[TBL] [Abstract][Full Text] [Related]
19. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Olszanecka-Glinianowicz M; Kuglin D; Dąbkowska-Huć A; Skałba P
Eur J Obstet Gynecol Reprod Biol; 2011 Jan; 154(1):51-6. PubMed ID: 20889251
[TBL] [Abstract][Full Text] [Related]
20. The impact of androgen levels on serum metabolic profiles in patients with polycystic ovary syndrome.
Ting Z; Xinghua T; Xiao X; Lingchuan L; Xiaomei W; Tao Y
Gynecol Endocrinol; 2024 Dec; 40(1):2352136. PubMed ID: 38733359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
